Sangamo (SGMO): חובות לטווח קצר של החברה
Sangamo Therapeutics (SGMO) generates revenue by developing gene therapy methods and tools for editing the code of life, securing funding through collaborations with pharmaceutical industry behemoths. The business focuses on combating severe genetic pathologies using advanced molecular approaches. This market trend visualized in monetary format on GURU.Markets with a value of 0.00 confirms the company's leadership in the field of zinc finger nucleases and its robust patent protection.
פילוחי נתונים אנליטיים מרוכזים עבור Sangamo BioSciences (SGMO)
The operational resilience of Sangamo Therapeutics (SGMO) is directly reflected in its total short-term debt. This indicator aggregates all obligations maturing within one year, determining current liquidity. Analyzing payment dynamics allows for the identification of hidden refinancing costs and capital risks. For a biopharmaceutical vendor with deep B2B integration into R&D chains, this metric confirms financial stability while scaling its AI platform. Low volatility in this series indicates high asset quality.